Company
Anatara Lifesciences Limited
Headquarters: Carlton, VIC, Australia
Market Cap
A$3.7 Million
AUD as of Jan. 1, 2024
US$2.5 Million
Anatara Lifesciences Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Anatara Lifesciences Limited engages in the research and development of evidence based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming (GaRP), a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD); and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets. In addition, it is developing bromelain-based formulations for piglets and poultry. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Anatara Lifesciences Limited has the following listings and related stock indices.
Stock: ASX: ANR wb_incandescent